Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
Cathie Wood's Buying These 3 Stocks Hand Over Fist
07:23am, Friday, 08'th Sep 2023
Cathie Wood recently bought shares of Beam Therapeutics, a clinical-stage drugmaker testing out a new way to edit troublesome genes. Ark Invest also acquired shares of Pacific Biosciences of Californi
Here's Why You Should Retain PacBio (PACB) Stock for Now
01:32pm, Tuesday, 05'th Sep 2023
PacBio's (PACB) product development activities raise optimism about the stock.
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:00am, Wednesday, 09'th Aug 2023
Cathie Wood bought shares of Palantir, PacBio, and Global-e Online on Tuesday. Palantir posted its weakest quarterly revenue growth as a public company, but it still exceeded its earlier guidance.
PacBio (PACB) Inks Research Collaboration for Genome Sequencing
09:58am, Wednesday, 09'th Aug 2023
PacBio (PACB) and GeneDx sign a deal with the University of Washington to study long-read sequencing in rare diseases. The study will use PacBio's Revio system to explore novel variants.
PacBio (PACB) Tops on Q2 Earnings, Raises FY23 Revenue View
03:00pm, Thursday, 03'rd Aug 2023
PacBio (PACB) witnesses strong revenue growth in the second quarter, partly aided by customers' product transition to the Revio system.
Pacific Biosciences of California (PACB) Reports Q2 Loss, Tops Revenue Estimates
07:28pm, Wednesday, 02'nd Aug 2023
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.34 per share a year ago.
Pacific Biosciences of California (PACB) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:43am, Wednesday, 26'th Jul 2023
Pacific Biosciences (PACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PacBio (PACB) Gets New Order for Revio System From Bioscientia
10:43am, Friday, 30'th Jun 2023
PacBio (PACB) receives new order for its Revio system from Bioscientia that will boost the latter's services. Here's how Revio can help Bioscientia improve diagnosis and treatment for monogenic disord
PacBio's (PACB) New Tie-Up to Boost Rare Disease Research
01:16pm, Tuesday, 20'th Jun 2023
PacBio's (PACB) latest collaboration is expected to highlight the feasibility and cost-effectiveness of using its HiFi sequencing technology.
Here's Why You Should Retain PacBio (PACB) Stock for Now
01:09pm, Friday, 02'nd Jun 2023
PacBio's (PACB) product development activities raise optimism about the stock.
PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View
12:55pm, Wednesday, 03'rd May 2023
PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
06:23pm, Tuesday, 02'nd May 2023
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.37 per share a year ago.
Assessing Pacific Biosciences And Their Revio Launch
06:34pm, Friday, 21'st Apr 2023
Assessing Pacific Biosciences And Their Revio Launch.
All You Need to Know About Pacific Biosciences (PACB) Rating Upgrade to Buy
01:02pm, Tuesday, 11'th Apr 2023
Pacific Biosciences (PACB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PacBio's (PACB) New Offering to Enable High-Throughput Workflows
12:16pm, Tuesday, 11'th Apr 2023
PacBio's (PACB) latest launch is expected to combine the power of HiFi sequencing and Nanobind technology to optimize sample preparation workflows for its high-volume customers.
